My Member
Message Center
trending topics
market reports
-
MEDICAL JAPAN 2025 OSAKA Returns to Showcase Global Innovations
2025-02-17
-
Visit MEDICAL JAPAN 2023 TOKYO and take full advantage of the business opportunities!
2023-09-01
-
US to distribute 400 million free N95 masks at CVS, Walgreens in COVID fight
2022-01-21
-
Ethiopia receives additional 2.2 mln doses of Chinese-donated COVID-19 vaccines
2022-01-21
-
Hong Kong researchers say they develop novel material able to kill COVID-19 virus
2022-01-14
-
10 million more Chinese doses on way for Kenya
2022-01-14
-
Sino-African ties on track for a brighter future
2022-01-07
-
Efforts urged to boost COVID-19 vaccine production capacity in poor countries
2022-01-07
-
UAE approves Sinopharm's new protein-based COVID-19 vaccine
2022-01-07
-
UAE approves Sinopharm's new protein-based COVID-19 vaccine
2022-01-07
Sinopharm's vaccine shows protection rate of over 79%
2020-12-30
[Photo/VCG]
Sinopharm's COVID-19 vaccine can induce neutralizing antibody in 99.52 percent of recipients, and has a 79.34 percent efficacy rate, according to midterm clinical results released on Wednesday.
The inactivated vaccine candidate created by Sinopharm's Beijing Biological Products Institute is generally safe, and a high level of neutralizing antibodies can be detected in 99.52 percent of the recipients after two doses, the company said in a statement on Wednesday.
The vaccine is also 79.34 percent effective at preventing the symptoms of COVID-19, meaning it has met the requirement by the World Health Organization and the National Medical Products Administration. Now, the company has official submitted its request for market approval to the administration, it said.
(China Daily)
